Trial · NCT02401048
Results by group34
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 34
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase 1b/2 : Overall Response Rate of Number of Participants | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | 7 | Participants | ||
| Phase 1b/2 : Overall Response Rate of Number of Participants | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort | 8 | Participants | ||
| Phase 1b/ 2: Duration of Response | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | 11.3 | 95% Confidence Interval 8.3 to NA | Months | |
| Phase 1b/ 2: Duration of Response | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort | NA | 95% Confidence Interval 2.5 to NA | Months | |
| Phase 1b/ 2: Progression-free Survival (PFS) | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | 10.2 | 95% Confidence Interval 4.7 to 13.1 | Months | |
| Phase 1b/ 2: Progression-free Survival (PFS) | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort | 2.6 | 95% Confidence Interval 1.5 to 4.4 | Months | |
| Phase 1b/2: Overall Survival | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | NA | 95% Confidence Interval 23.6 to NA | Months | |
| Phase 1b/2: Overall Survival | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort | 5.1 | 95% Confidence Interval 3.7 to 10.1 | Months | |
| Phamacokinetics: Mean Maximum Observed Plasma Concentration (Cmax) for Ibrutinib | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | Lead-In Day 6/7 | 196 | Standard Deviation 245 | ng/mL |
| Phamacokinetics: Mean Maximum Observed Plasma Concentration (Cmax) for Ibrutinib | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort | Lead-In Day 6/7 | 140 | Standard Deviation 117 | ng/mL |
| Phamacokinetics: Mean Maximum Observed Plasma Concentration (Cmax) for Ibrutinib | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | Cycle 3 Day 1 | 155 | Standard Deviation 102 | ng/mL |
| Phamacokinetics: Mean Maximum Observed Plasma Concentration (Cmax) for Ibrutinib | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort | Cycle 3 Day 1 | 183 | Standard Deviation 101 | ng/mL |
| Pharmacokinetics: Mean Time to Maximum Observed Plasma Concentration (Tmax) for Ibrutinib | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | Lead-In Day 6/7 | 1.95 | Full Range 0.750 to 4.00 | hour |
| Pharmacokinetics: Mean Time to Maximum Observed Plasma Concentration (Tmax) for Ibrutinib | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort | Lead-In Day 6/7 | 2.01 | Full Range 0.930 to 6.00 | hour |
| Pharmacokinetics: Mean Time to Maximum Observed Plasma Concentration (Tmax) for Ibrutinib | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | Cycle 3 Day 1 | 2.00 | Full Range 1.00 to 6.05 | hour |
| Pharmacokinetics: Mean Time to Maximum Observed Plasma Concentration (Tmax) for Ibrutinib | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort | Cycle 3 Day 1 | 2.07 | Full Range 1.00 to 4.97 | hour |
| Pharmacokinetics: Mean Area Under the Plasma Concentration-Time Curve From Time 0-24 Hours (AUC0-24h) for Ibrutinib | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | Lead-In Day 6/7 | 1078 | Standard Deviation 1013 | ng*h/mL |
| Pharmacokinetics: Mean Area Under the Plasma Concentration-Time Curve From Time 0-24 Hours (AUC0-24h) for Ibrutinib | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort | Lead-In Day 6/7 | 936 | Standard Deviation 691 | ng*h/mL |
| Pharmacokinetics: Mean Area Under the Plasma Concentration-Time Curve From Time 0-24 Hours (AUC0-24h) for Ibrutinib | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | Cycle 3 Day 1 | 1096 | Standard Deviation 748 | ng*h/mL |
| Pharmacokinetics: Mean Area Under the Plasma Concentration-Time Curve From Time 0-24 Hours (AUC0-24h) for Ibrutinib | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort | Cycle 3 Day 1 | 1606 | Standard Deviation 901 | ng*h/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02401048/results